Sensorion: Reporting of the General Assembly

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering
clinical-stage biopharmaceutical company which specialises in the
development of novel therapies to restore, treat and prevent inner ear
diseases such as hearing loss, tinnitus and vertigo held its combined
general meeting on May 28, 2019.

The Combined Ordinary and Extraordinary General Shareholders’ Meeting,
held in Paris on May 28, 2019, under the chairmanship of Patrick
Langlois, adopted the resolutions submitted to the vote of the general
meeting, including the approval of the 2018 company financial statements
and the renewal of delegations and financial authorizations (with the
exception of resolution 20 concerning the authorization of a capital
increase reserved for employees participating in a PEE, ”Plan Epargne
d’Entreprise”, company’ saving plan).

Patrick Langlois introduced the session by indicating that the year 2018
was marked by an important increase in research and development spending
due to the progression of SENS-111 clinical trial in acute unilateral
vestibulopathy (AUV) and the start of the phase 2 SENS-401 in Sudden
Sensorineural Hearing Loss (SSNHL).

As a reminder of the press release of May 27th, 2019, the recent
signature of the partnership framework agreement with Institut Pasteur
on gene therapy programs targeting hearing loss was mentioned.

Finally, in order to meet the Company’s cash requirements and ensure
going concern, it was reminded that the company was actively seeking
financing from institutional investors as well as from public and
private entities. financial institutions for grants and / or repayable
advances relating to the Company’s research programs.

The main events expected for 2019 are summarized below and appear in the
presentation of the general assembly available on the website.

About Sensorion

Sensorion is a pioneering clinical-stage biopharmaceutical company,
which specializes in the development of novel therapies to restore,
treat and prevent inner ear diseases such as hearing loss, vertigo and
tinnitus. Our clinical-stage portfolio includes two phase 2 products:
Seliforant (SENS-111) under investigation for acute unilateral
vestibulopathy and Arazasetron (SENS-401) for sudden sensorineural
hearing loss (SSNHL). We have built a unique R&D technology platform to
expand our understanding of the physiopathology and etiology of inner
ear related diseases enabling us to select the best targets and
modalities for drug candidates. We also identify biomarkers to improve
diagnosis and treatment of these underserved illnesses.

We are uniquely placed through our platforms and pipeline of potential
therapeutics to make a lasting positive impact on hundreds of thousands
of people with inner ear related disorders; a significant global unmet
need in medicine today.

www.sensorion-pharma.com

Label: SENSORION
ISIN: FR0012596468
Mnemonic: ALSEN

Disclaimer

This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward-looking statements
are based on assumptions that Sensorion considers to be reasonable.
However, there can be no assurance that such forward-looking statements
will be verified, which statements are subject to numerous risks,
including the risks set forth in the Document de référence registration
document filed with the Autorité des marchés financiers (AMF- French
Financial Market Authority) on September 6, 2017 under n°R.17-062 and to
the development of economic conditions, financial markets and the
markets in which Sensorion operates. The forward-looking statements
contained in this press release are also subject to risks not yet known
to Sensorion or not currently considered material by Sensorion. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Sensorion to be
materially different from such forward-looking statements.

This press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of an
offer to purchase or subscribe for, Sensorion shares in any country. The
communication of this press release in certain countries may constitute
a violation of local laws and regulations. Any recipient of this press
release must inform oneself of any such local restrictions and comply
therewith.

Contacts

Sensorion
Nawal Ouzren
CEO
[email protected]
Tel:
+33 467 207 730

Catherine Leveau
Financial communication
[email protected]
Tel:
+33 467 207 730